Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress [RNASeq]

ABSTRACT: Oncogenic RAS activation, hypertranscription and transcription-replication conflicts (TRCs) are frequent features of cancer cells that are under investigation for therapeutic targeting. RAS oncogenes promote RNA polymerase activity and hypertranscription for cell growth and proliferation, which can the lead to TRCs. Here, we investigated hypertranscription and replication stress induced by the HRAS and KRAS oncogenes, and their downstream signalling through the MAPK and PI3K pathways. We show that HRAS causes more TRCs than KRAS because HRAS specifically hyperactivates the PI3K-AKT signalling pathway. MAPK signalling is insufficient to cause hypertranscription and TRCs, which require PI3K activity. PI3K hyperactivation was associated with increased E2F and MYC transcription programmes, increased S phase entry, increased nascent transcription of genes encoding ribosome biogenesis factors and expression of small nucleolar RNAs (snoRNAs). Inhibiting S phase entry alone did not rescue hypertranscription and replication stress, which required both MAPK and PI3K signalling. We report that a main downstream effector of PI3K-induced hypertranscription is AKT-mediated phosphorylation of GSK3b, which stabilises MYC. Cancer datasets further support that PI3K mutations may be associated with hypertranscription and replication stress signatures. Our findings suggest a mechanistic explanation for replication stress variability across RAS models and identify potential new predictors of TRCs in cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE322525 | GEO | 2026/03/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress [ChrRNAseq]

Project description:Oncogenic RAS activation, hypertranscription and transcription-replication conflicts (TRCs) are frequent features of cancer cells that are under investigation for therapeutic targeting. RAS oncogenes promote RNA polymerase activity and hypertranscription for cell growth and proliferation, which can the lead to TRCs. Here, we investigated hypertranscription and replication stress induced by the HRAS and KRAS oncogenes, and their downstream signalling through the MAPK and PI3K pathways. We show that HRAS causes more TRCs than KRAS because HRAS specifically hyperactivates the PI3K-AKT signalling pathway. MAPK signalling is insufficient to cause hypertranscription and TRCs, which require PI3K activity. PI3K hyperactivation was associated with increased E2F and MYC transcription programmes, increased S phase entry, increased nascent transcription of genes encoding ribosome biogenesis factors and expression of small nucleolar RNAs (snoRNAs). Inhibiting S phase entry alone did not rescue hypertranscription and replication stress, which required both MAPK and PI3K signalling. We report that a main downstream effector of PI3K-induced hypertranscription is AKT-mediated phosphorylation of GSK3b, which stabilises MYC. Cancer datasets further support that PI3K mutations may be associated with hypertranscription and replication stress signatures. Our findings suggest a mechanistic explanation for replication stress variability across RAS models and identify potential new predictors of TRCs in cancer.

2026-03-09 | GSE322524 | GEO

Human RNaseH2 subunit upregulation counteracts oncogene- and chemotherapy-induced replication stress

Project description:RNaseH2 is a heterotrimeric endoribonuclease that resolves RNA:DNA hybrids and mis-incorporated ribonucleotides, which are implicated in DNA replication stress and cancer development and potential therapeutic targets. Individual RNaseH2 subunit mRNA or protein levels are found elevated in some cancers, but little is known about the mechanisms behind and impact of RNaseH2 subunit upregulation. We report that RNaseH2 subunits are upregulated at the protein level in response to replication stress induced by oncogenes and chemotherapy drugs hydroxyurea, gemcitabine and camptothecin in human cancer and non-cancer cell lines. We show that inducible overexpression of the RNaseH2B subunit increases the levels of the whole active RNaseH2 complex and can counteract drug-induced RNA:DNA hybrid formation. RNaseH2B overexpression reduces replication fork stalling induced by camptothecin and hydroxyurea but can itself increase RNA:DNA hybrid levels and cause replication stress. RNaseH2 subunit levels do not strongly impact survival of chemotherapy drug treatments but may have more subtle effects on genomic instability and cytoplasmic DNA signalling. In contrast, increased RNaseH2 subunit levels in presence of oncogenic HRAS are required to limit not only RAS-induced replication fork stalling but also cell death. Our findings shed new light on the functions of RNaseH2 and suggest that upregulation of RNaseH2 subunits may be an important aspect of replication stress responses in cancer.

2024-12-16 | GSE276623 | GEO

Transcriptome analysis of skeletal muscle tissue from Hras G12V mutant mice

Project description:Costello syndrome (CS) is a congenital disorder caused by heterozygous activating germline HRAS mutations in the canonical Ras/mitogen-activated protein kinase (Ras/MAPK) pathway. CS is one of the RASopathies, a large group of syndromes due to mutations within various components of the Ras/MAPK pathway. An important part of the phenotype that greatly impacts quality of life is hypotonia. To gain a better understanding of the mechanisms underlying hypotonia in CS, a mouse model with an activating HrasG12V allele was utilized. We identified a skeletal myopathy that was due in part to an inhibition of embryonic myogenesis and myofiber formation, resulting in a reduction of myofiber size and number that led to reduced muscle mass and strength. In addition to hyperactivation of the Ras/MAPK and PI3K/AKT pathways, there was a significant reduction of p38 signaling, as well as global transcriptional alterations consistent with the myopathic phenotype. Inhibition of Ras/MAPK pathway signaling using a MEK inhibitor rescued the HrasG12V myopathy phenotype both in vitro and in vivo, demonstrating that increased MAPK signaling is the main cause of the muscle phenotype in CS.

2021-11-16 | GSE187493 | GEO

Oncogenic YAP sensitizes cells to CHK1 inhibition via CDK4/6 driven G1 acceleration

Project description:Replication stress is a driver of genomic instability, contributing to carcinogenesis by causing DNA damage and mutations. While YAP, the downstream co-activator of the Hippo signaling pathway, plays a crucial role in regulating cell growth and differentiation, it is unclear whether it generates replication stress exploitable for therapy. Here, we report that oncogenic YAP shortens the G1 phase through increased CDK4/6 activity, leading to early S-phase entry. This causes origin under-licensing, an overall reduced rate of DNA replication, and, untypically, an accelerated speed of individual replication forks. CHK1 inhibition in cells expressing oncogenic YAP results in DNA damage during S-phase, which is not due to premature CDK1 activation or mitotic entry. Sensitivity to CHK1 inhibition depends on the YAP-TEAD interaction and involves a global increase in transcription and an increase in transcription-replication conflicts (TRCs). Replication stress from oncogenic YAP can be mitigated by restoring G1 length through partial CDK4/6 inhibition or by reducing YAP-induced hypertranscription. Our findings suggest a potential therapeutic strategy for targeting YAP-dependent cancers by exploiting their vulnerability to replication stress.

2025-07-01 | GSE296501 | GEO

Structural analysis of neurofibromin by crosslinking mass spectrometry

Project description:Neurofibromin (NF1) is a fundamental inhibitor of cell growth that is conserved from yeast to humans. NF1 negatively regulates oncogenic RAS proteins by accelerating the hydrolysis of RAS-bound GTP. This activity blocks growth factor signalling upstream of both mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. However, the structure and regulatory mechanisms of NF1 have remained elusive. Here we report crosslinking mass spectrometry analysis of the 320 kDa NF1 protein.

2022-08-12 | PXD023593 | Pride

RNAPII-dependent ATM signaling at collisions with replication forks [CUT&RUN]

Project description:Deregulation of RNA Polymerase II (RNAPII) by oncogenic signaling leads to collisions of RNAPII with DNA synthesis machinery (transcription-replication conflicts, TRCs). TRCs can result in DNA damage and underlie genomic instability in tumor cells. Here we provide evidence that elongating RNAPII promotes activation of the ATM kinase at TRCs to drive DNA repair. We show the ATPase Wrnip1 that binds and protects stalled replication forks, associates with RNAPII and limits ATM activation. Wrnip1 binding to elongating RNAPII requires catalytic activity of the ubiquitin ligase Huwe1. Mutation of Huwe1 promotes the transfer of Wrnip1 onto replisome and induces TRCs stimulating ATM activation on RNAPII. This mechanism is evoked early upon replicative stress to induce Wrnip1 translocation and ATM signaling at TRCs. Thus, although primarily considered as genotoxic events, TRCs can provide a mechanism to maintain genome stability under replicative stress.

2023-08-01 | GSE218238 | GEO

RNAPII-dependent ATM signaling at collisions with replication forks [ChIP-seq]

2023-08-01 | GSE218237 | GEO

RNAPII-dependent ATM signaling at collisions with replication forks [RNA-seq]

2023-08-01 | GSE218236 | GEO

RNAPII-dependent ATM signaling at collisions with replication forks [DSBCapture]

2023-08-01 | GSE222839 | GEO

RNAPII-dependent ATM signaling at collisions with replication forks [DSB]

2023-08-01 | GSE218239 | GEO